NS 300

Drug Profile

NS 300

Alternative Names: NS300

Latest Information Update: 24 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Neuracle Science
  • Class Antibodies; Antiepileptic drugs; Neuropsychotherapeutics
  • Mechanism of Action Neuropeptide modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Neuropathic pain
  • Research Autistic disorder; Epilepsy; Schizophrenia

Most Recent Events

  • 24 Jan 2018 Early research in Autistic disorder in South Korea (Parenteral) before January 2018 (Neuracle Science pipeline, January 2018)
  • 24 Jan 2018 Early research in Epilepsy in South Korea (Parenteral) before January 2018 (Neuracle Science pipeline, January 2018)
  • 24 Jan 2018 Early research in Schizophrenia in South Korea (Parenteral) before January 2018 (Neuracle Science pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top